Acrobiosystems Co.Ltd.
Acrobiosystems Co.,Ltd. engages in the development and manufacture of recombinant proteins, antibodies, and other biological reagents for pharmaceutical and biotechnology companies, and scientific research institutions. The company has a collaboration with Diagnostic Biochips Inc for neurological drug discovery and commercialization. The company was founded in 2010 and is based in Beijing, China.
Acrobiosystems Co.Ltd. (301080) - Net Assets
Latest net assets as of June 2025: CN¥2.61 Billion CNY
Based on the latest financial reports, Acrobiosystems Co.Ltd. (301080) has net assets worth CN¥2.61 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.88 Billion) and total liabilities (CN¥268.57 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.61 Billion |
| % of Total Assets | 90.67% |
| Annual Growth Rate | 93.01% |
| 5-Year Change | 1204.98% |
| 10-Year Change | N/A |
| Growth Volatility | 443.73 |
Acrobiosystems Co.Ltd. - Net Assets Trend (2019–2024)
This chart illustrates how Acrobiosystems Co.Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Acrobiosystems Co.Ltd. (2019–2024)
The table below shows the annual net assets of Acrobiosystems Co.Ltd. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.61 Billion | +0.87% |
| 2023-12-31 | CN¥2.59 Billion | +0.76% |
| 2022-12-31 | CN¥2.57 Billion | +4.17% |
| 2021-12-31 | CN¥2.47 Billion | +1132.62% |
| 2020-12-31 | CN¥200.06 Million | +105.53% |
| 2019-12-31 | CN¥97.34 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Acrobiosystems Co.Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 831.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥334.20 Million | 12.78% |
| Other Components | CN¥2.28 Billion | 87.22% |
| Total Equity | CN¥2.62 Billion | 100.00% |
Acrobiosystems Co.Ltd. Competitors by Market Cap
The table below lists competitors of Acrobiosystems Co.Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
JINXIN FERT.GRP HD-00001
F:3NX
|
$536.60 Million |
|
Alandsbanken Abp A
HE:ALBAV
|
$536.86 Million |
|
Guangzhou Risong Intelligent Technology Holding Co Ltd
SHG:688090
|
$537.21 Million |
|
American Woodmark Corporation
NASDAQ:AMWD
|
$537.29 Million |
|
Kuyas Yatirim AS
IS:KUYAS
|
$536.46 Million |
|
Tele Columbus AG
LSE:0R50
|
$536.46 Million |
|
AMC Entertainment Holdings Inc
NYSE:AMC
|
$536.31 Million |
|
Shenyang Jinbei Automotive Co Ltd
SHG:600609
|
$536.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Acrobiosystems Co.Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,589,558,266 to 2,615,654,173, a change of 26,095,907 (1.0%).
- Net income of 123,832,480 contributed positively to equity growth.
- Dividend payments of 108,213,665 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥123.83 Million | +4.73% |
| Dividends Paid | CN¥108.21 Million | -4.14% |
| Other Changes | CN¥10.48 Million | +0.4% |
| Total Change | CN¥- | 1.01% |
Book Value vs Market Value Analysis
This analysis compares Acrobiosystems Co.Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.01x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 27.05x to 2.01x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥1.62 | CN¥43.91 | x |
| 2020-12-31 | CN¥2.23 | CN¥43.91 | x |
| 2021-12-31 | CN¥14.68 | CN¥43.91 | x |
| 2022-12-31 | CN¥15.26 | CN¥43.91 | x |
| 2023-12-31 | CN¥15.41 | CN¥43.91 | x |
| 2024-12-31 | CN¥21.80 | CN¥43.91 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Acrobiosystems Co.Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.73%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 19.20%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 1.11x
- Recent ROE (4.73%) is below the historical average (15.82%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 11.40% | 10.75% | 0.91x | 1.17x | CN¥1.36 Million |
| 2020 | 57.85% | 47.05% | 1.02x | 1.20x | CN¥95.85 Million |
| 2021 | 7.06% | 45.25% | 0.15x | 1.03x | CN¥-72.48 Million |
| 2022 | 7.95% | 42.94% | 0.17x | 1.07x | CN¥-52.59 Million |
| 2023 | 5.93% | 28.25% | 0.19x | 1.09x | CN¥-105.36 Million |
| 2024 | 4.73% | 19.20% | 0.22x | 1.11x | CN¥-137.73 Million |
Industry Comparison
This section compares Acrobiosystems Co.Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $5,249,192,405
- Average return on equity (ROE) among peers: 10.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Acrobiosystems Co.Ltd. (301080) | CN¥2.61 Billion | 11.40% | 0.10x | $536.56 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $85.28 Million | -13.04% | 0.97x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $687.82 Million | 11.47% | 1.00x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $134.48 Million | 10.88% | 3.14x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $915.76 Million | -0.65% | 0.06x | $253.71 Million |
| Chengzhi Shareholding Co Ltd (000990) | $997.75 Million | 5.11% | 1.23x | $934.96 Million |
| Hualan Biological EngineeringInc (002007) | $6.88 Billion | 18.64% | 0.10x | $1.99 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $7.66 Billion | 47.23% | 0.35x | $793.09 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $31.94 Billion | 6.87% | 0.05x | $3.75 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $403.60 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $1.14 Billion | 14.05% | 0.13x | $344.80 Million |